Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Foghorn Therapeutics Inc. - Common Stock (NQ:FHTX)

5.260 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Foghorn Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Foghorn Therapeutics Shifts Focus from Development Of Cancer Hopeful with Eye Cancer
Foghorn Therapeutics Inc (NASDAQ: FHTX) announced the data from the Phase 1 dose escalation safety study of FHD-286 in  
Via Benzinga
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
What 6 Analyst Ratings Have To Say About Foghorn Therapeutics
 
Via Benzinga
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Analyst Expectations for Foghorn Therapeutics's Future
 
Via Benzinga
Expert Ratings for Foghorn Therapeutics
 
Via Benzinga
Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Crude Oil Up 1.5%; Philips Shares Jump After Q1 Results
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping around 40 points on Monday. The Dow traded up 0.05% to 33,827.42 while the NASDAQ fell 0.33% to 12,032.16.... 
Via Benzinga
Foghorn Therapeutics Earnings Perspective: Return On Capital Employed
 
Via Benzinga
Why IDEAYA Biosciences Shares Are Trading Higher By Around 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Aclarion, Inc. (NASDAQ: ACON) shares surged 152% to $1.85 amid the publication of durability data for the company's back pain treatment. 
Via Benzinga
US Stocks Turn Lower; Nasdaq Dips 100 Points
U.S. stocks turned lower midway through trading, with the Nasdaq Composite dropping around 100 points on Monday. The Dow traded down 0.19% to 33,744.92 while the NASDAQ fell 0.84% to 11,971. The S&P... 
Via Benzinga
More Trouble For Foghorn Therapeutics: After Blood Cancer Trial, FDA Puts Another Cancer Trial On Clinical Hold
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Foghorn Therapeutics Provides an Update on FHD-609
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286, a Potent, Selective Inhibitor of BRG1 and BRM, at the 2023 American Association for Cancer Research Annual
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023
 
Via Benzinga
Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Participate at Cowen’s 43rd Annual Health Care Conference
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Why Altimmune, Foghorn Therapeutics, and Precigen Shares Crashed This Week
Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week. 
Via The Motley Fool
Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML to Be Presented at the American Society of Hematology Annual Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  During Wednesday's session, 107 stocks hit new 52-week lows. 
Via Benzinga
Foghorn Therapeutics to Participate at the Evercore ISI HealthCONx Conference
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Present at Connective Tissue Oncology Society Annual Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Present New Preclinical Data for BRG1/BRM Inhibitor FHD-286 in Combination with Anti-PD-1 Antibody at Society for Immunotherapy of Cancer 37th Annual Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback